Literature DB >> 30225211

Autochthonous murine models for the study of smoker and never-smoker associated lung cancers.

Esra A Akbay1,2, James Kim2,3.   

Abstract

Lung cancer accounts for the greatest number of cancer deaths in the world. Tobacco smoke-associated cancers constitute the majority of lung cancer cases but never-smoker cancers comprise a significant and increasing fraction of cases. Recent genomic and transcriptomic sequencing efforts of lung cancers have revealed distinct sets of genetic aberrations of smoker and never-smoker lung cancers that implicate disparate biology and therapeutic strategies. Autochthonous mouse models have contributed greatly to our understanding of lung cancer biology and identified novel therapeutic targets and strategies in the era of targeted therapy. With the emergence of immuno-oncology, mouse models may continue to serve as valuable platforms for novel biological insights and therapeutic strategies. Here, we will review the variety of available autochthonous mouse models of lung cancer, their relation to human smoker and never-smoker lung cancers, and their application to immuno-oncology and immune checkpoint blockade that is revolutionizing lung cancer therapy.

Entities:  

Keywords:  Lung cancer; mouse models; never-smoker; smoker

Year:  2018        PMID: 30225211      PMCID: PMC6131182          DOI: 10.21037/tlcr.2018.06.04

Source DB:  PubMed          Journal:  Transl Lung Cancer Res        ISSN: 2218-6751


  217 in total

1.  Synergistic Immunostimulatory Effects and Therapeutic Benefit of Combined Histone Deacetylase and Bromodomain Inhibition in Non-Small Cell Lung Cancer.

Authors:  Dennis O Adeegbe; Yan Liu; Patrick H Lizotte; Yusuke Kamihara; Amir R Aref; Christina Almonte; Ruben Dries; Yuyang Li; Shengwu Liu; Xiaoen Wang; Tiquella Warner-Hatten; Jessica Castrillon; Guo-Cheng Yuan; Neermala Poudel-Neupane; Haikuo Zhang; Jennifer L Guerriero; Shiwei Han; Mark M Awad; David A Barbie; Jerome Ritz; Simon S Jones; Peter S Hammerman; James Bradner; Steven N Quayle; Kwok-Kin Wong
Journal:  Cancer Discov       Date:  2017-04-13       Impact factor: 39.397

2.  Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras.

Authors:  E L Jackson; N Willis; K Mercer; R T Bronson; D Crowley; R Montoya; T Jacks; D A Tuveson
Journal:  Genes Dev       Date:  2001-12-15       Impact factor: 11.361

3.  ROS1 rearrangements define a unique molecular class of lung cancers.

Authors:  Kristin Bergethon; Alice T Shaw; Sai-Hong Ignatius Ou; Ryohei Katayama; Christine M Lovly; Nerina T McDonald; Pierre P Massion; Christina Siwak-Tapp; Adriana Gonzalez; Rong Fang; Eugene J Mark; Julie M Batten; Haiquan Chen; Keith D Wilner; Eunice L Kwak; Jeffrey W Clark; David P Carbone; Hongbin Ji; Jeffrey A Engelman; Mari Mino-Kenudson; William Pao; A John Iafrate
Journal:  J Clin Oncol       Date:  2012-01-03       Impact factor: 44.544

4.  The differential effects of mutant p53 alleles on advanced murine lung cancer.

Authors:  Erica L Jackson; Kenneth P Olive; David A Tuveson; Roderick Bronson; Denise Crowley; Michael Brown; Tyler Jacks
Journal:  Cancer Res       Date:  2005-11-15       Impact factor: 12.701

Review 5.  The changing cigarette.

Authors:  D Hoffmann; M V Djordjevic; I Hoffmann
Journal:  Prev Med       Date:  1997 Jul-Aug       Impact factor: 4.018

6.  Lung cancer incidence in never smokers.

Authors:  Heather A Wakelee; Ellen T Chang; Scarlett L Gomez; Theresa H Keegan; Diane Feskanich; Christina A Clarke; Lars Holmberg; Lee C Yong; Laurence N Kolonel; Michael K Gould; Dee W West
Journal:  J Clin Oncol       Date:  2007-02-10       Impact factor: 44.544

7.  TGF-beta IL-6 axis mediates selective and adaptive mechanisms of resistance to molecular targeted therapy in lung cancer.

Authors:  Zhan Yao; Silvia Fenoglio; Ding Cheng Gao; Matthew Camiolo; Brendon Stiles; Trine Lindsted; Michaela Schlederer; Chris Johns; Nasser Altorki; Vivek Mittal; Lukas Kenner; Raffaella Sordella
Journal:  Proc Natl Acad Sci U S A       Date:  2010-08-16       Impact factor: 11.205

8.  Favorable clinical outcomes of pemetrexed treatment in anaplastic lymphoma kinase positive non-small-cell lung cancer.

Authors:  Ha Yeon Lee; Hee Kyung Ahn; Ji Yun Jeong; Mi Jung Kwon; Jung-Ho Han; Jong-Mu Sun; Jin Seok Ahn; Keunchil Park; Yoon-La Choi; Myung-Ju Ahn
Journal:  Lung Cancer       Date:  2012-10-25       Impact factor: 5.705

9.  Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer.

Authors:  Hossein Borghaei; Luis Paz-Ares; Leora Horn; David R Spigel; Martin Steins; Neal E Ready; Laura Q Chow; Everett E Vokes; Enriqueta Felip; Esther Holgado; Fabrice Barlesi; Martin Kohlhäufl; Oscar Arrieta; Marco Angelo Burgio; Jérôme Fayette; Hervé Lena; Elena Poddubskaya; David E Gerber; Scott N Gettinger; Charles M Rudin; Naiyer Rizvi; Lucio Crinò; George R Blumenschein; Scott J Antonia; Cécile Dorange; Christopher T Harbison; Friedrich Graf Finckenstein; Julie R Brahmer
Journal:  N Engl J Med       Date:  2015-09-27       Impact factor: 91.245

10.  Uncoupling cancer mutations reveals critical timing of p53 loss in sarcomagenesis.

Authors:  Nathan P Young; Denise Crowley; Tyler Jacks
Journal:  Cancer Res       Date:  2011-04-21       Impact factor: 12.701

View more
  5 in total

1.  EGFR inhibition triggers an adaptive response by co-opting antiviral signaling pathways in lung cancer.

Authors:  Ke Gong; Gao Guo; Nishah Panchani; Matthew E Bender; David E Gerber; John D Minna; Farjana Fattah; Boning Gao; Michael Peyton; Kemp Kernstine; Bipasha Mukherjee; Sandeep Burma; Cheng-Ming Chiang; Shanrong Zhang; Adwait Amod Sathe; Chao Xing; Kathryn H Dao; Dawen Zhao; Esra A Akbay; Amyn A Habib
Journal:  Nat Cancer       Date:  2020-04-06

2.  Heterogeneity of neoantigen landscape between primary lesions and their matched metastases in lung cancer.

Authors:  Tao Jiang; Ruirui Cheng; Yuanwei Pan; Henghui Zhang; Ying He; Chunxia Su; Shengxiang Ren; Caicun Zhou
Journal:  Transl Lung Cancer Res       Date:  2020-04

3.  Comprehensive targeting of resistance to inhibition of RTK signaling pathways by using glucocorticoids.

Authors:  Ke Gong; Gao Guo; Nicole A Beckley; Xiaoyao Yang; Yue Zhang; David E Gerber; John D Minna; Sandeep Burma; Dawen Zhao; Esra A Akbay; Amyn A Habib
Journal:  Nat Commun       Date:  2021-12-01       Impact factor: 14.919

4.  Reduced Chronic Toxicity and Carcinogenicity in A/J Mice in Response to Life-Time Exposure to Aerosol From a Heated Tobacco Product Compared With Cigarette Smoke.

Authors:  Ee Tsin Wong; Karsta Luettich; Subash Krishnan; Sin Kei Wong; Wei Ting Lim; Demetrius Yeo; Ansgar Büttner; Patrice Leroy; Grégory Vuillaume; Stéphanie Boué; Julia Hoeng; Patrick Vanscheeuwijck; Manuel C Peitsch
Journal:  Toxicol Sci       Date:  2020-11-01       Impact factor: 4.849

Review 5.  Current methods in translational cancer research.

Authors:  Michael W Lee; Mihailo Miljanic; Todd Triplett; Craig Ramirez; Kyaw L Aung; S Gail Eckhardt; Anna Capasso
Journal:  Cancer Metastasis Rev       Date:  2020-09-14       Impact factor: 9.264

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.